Company Overview and News
“Centrica delivered a solid first half financial performance despite reduced energy demand due to warm weather and strong competitive pressures, and we remain on track to achieve the 2017 targets we set out in February. We have made further significant strategic progress, continuing to reallocate resources away from our asset businesses towards our customer-facing businesses. With the announced asset disposals and the creation of a new European E&P joint venture, we expect the first phase of our portfolio transformation to be complete by the end of 2017, leaving the Group well-positioned to deliver longer-term returns and growth.
Centrica PLC, Windsor, UK, has agreed to merge its European oil and gas exploration and production business with Bayerngas Norge AS, Oslo, to form a newly incorporated joint venture.
Chicago, IL – June 14, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include SemGroup Corp. (NYSE: (SEMG - Free Report) – Free Report ), Encana Corp. (NYSE: (ECA - Free Report) – Free Report ), Centrica plc (OTCMKTS: (CPYYY - Free Report) – Free Report ), Eni SpA (NYSE: (E - Free Report) – Free Report ) and Petrobras (NYSE: (PBR - Free Report) – Free Report ).
It was a week where oil prices dropped to the lowest close since May 4 amid a bearish inventory data, while supportive weather forecasts pushed natural gas futures higher.
British energy supplier Centrica plc (CPYYY - Free Report) recently announced that it is about to divest its Canadian oil and gas exploration and production joint venture – CQ Energy Canada Partnership – to a consortium that includes, among others, Hong Kong-listed energy company MIE Holdings Corporation. Centrica owns 60% operating interests in the properties that mostly produce natural gas.
June 9 (Reuters) - Britain's largest energy supplier, Centrica Plc, said it would sell its 60 percent stake in its Canadian oil and gas exploration and production joint venture to a consortium for about 240 million pounds ($305 million).
The UK’s largest energy companies may have been handed a stay of execution from threatened energy price caps amid the chaos of the general election outcome.
The CQ Energy Canada Partnership ("CQ"), the Canadian E&P joint venture in which Centrica plc owns a 60% interest, is to be sold to a consortium comprising MIE Holdings Corporation ("MIE"), The Can-China Global Resource Fund and Mercuria for a purchase price of C$722 million (£413 million) in cash. Centrica's net share of sale proceeds is expected to be approximately £240 million after adjustments.
Singapore, whose economy relies on shipping and oil service firms, was exposed first because the companies were smaller and less able to tap government support. — Reuters picSINGAPORE, Dec 28 ― Singapore’s commodities-related defaults could turn out to be the canary in the mine.
HONG KONG (Dec 28): Singapore’s commodities-related defaults could turn out to be the canary in the mine.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
KUALA LUMPUR (Nov 16): Shareholders in Reach Energy Bhd have approved the company's proposed acquisition of a 60% stake in Palaeontol BV, which owns an onshore oil and gas field called Emir-Oil LLP in Kazakhstan.
Investors wanting exposure to small E&P companies may do well focusing on the micro-cap space rather than small-caps.
Shahul: ‘I have been in the industry for more than thirty years. This is not for the glory. Consider this my national service to Malaysia.’
CALGARY, ALBERTA--(Marketwired - Sept. 15, 2016) - MIE Maple Investments Limited ("MIE") announces that it has agreed to acquire an aggregate of 16,355,798 common shares and restricted voting shares (collectively, "Shares") in the capital of Journey Energy Inc. ("Journey") from Infra-PSP Partners Inc. for aggregate consideration of $33,846,602 (being an amount of approximately $2.069 per Share) pursuant to a share purchase agreement dated as of September 15, 2016.
2018-05-19 - Asif
OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...
2018-05-19 - Asif
Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...
2018-05-17 - Asif
Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...